A restrospective study carried out on 309 patients with chronic myelogenous leukemia treated from 1990 to 10/2000 showed that; -88 cases (28.3%) converted to the blast crisis. - 89.77% of these cases developed acute myeloblastic leukemia (AML) and 9.09% developed ALL.-The percentage of male and female were 55.68% and 44.31% - 45.45% of these converted cases occurred in the age group of 30-50. The youngest age was 10 months and the oldest age was : 72 years old. Mean of duration of the chronic phase was 2.5 years.
Leukemia, Myeloid, Chronic ; Leukemia, Myeloid, Chronic-Phase

A patient with the chronic myeloid leukemia received the autologous stem cells transplantation of peripheral blood. The results have shown that the patient was responded well with the autograft, the graft grew early as estimation. The patient also responded completely with the treatment by Hydrea. The clinical and hematological signs were stable in the long-term. The complication during transplantation was mild. The total survival duration was 75 months.
Leukemia, Myeloid, Chronic ; therapeutics

88 patients with the chronic myeloid leukemia treated with Hydrea during 1/1999 - 12/2000. Most of them admitted to the center for hematology and blood transfusion in the conditions of very high leukocytosis and acute mortality risk due to cerebrovascular obstruction. Patients indicated by high dose of Hydrea in average duration of treatment of 6.5 (1.8 days. The treatment with Hydrea demonstrated that the survival duration of patients was lasted. The drug had fewer side effects. The treatment was not expensive. This is suitable for economic conditions of patients in Vietnam.
Leukemia, Myeloid, Chronic ; therapeutics

No abstract available.
Leukemia, Myeloid, Acute* ; Leukemia, Myelomonocytic, Chronic*

No abstract available.
Leukemia, Lymphocytic, Chronic, B-Cell* ; Leukemia, Myeloid, Acute*

20 patients with acute leprosy, 12 patients with chronic hepatitis, 34 patients with acute myelogenous leukemia, 48 patients with pharynx cancer. 31 normal healthy persons in the control group. Immune-complexes were fixed quantity by 2 methods: precipitating the immune-complexes with PEG having molecular weight 6.10¬3 and better method. Immune-complexes (+) were identified on acute leprosy, chronic hepatitis and acute diseases with the ratio of positive differences depending on disease, stage and the character of applying technique
Leprosy ; Hepatitis, Chronic ; Pharyngeal Neoplasms ; Leukemia, Myeloid, Acute

Renal involvement by leukemic cells is rare in chronic myelogenous leukemia (CML). Herein, this study reports a case of CML associated with renal involvement of leukemic cells, which occurred 1 and 1/2 years after the initial diagnosis. Abdomino-pelvic computed tomography revealed a 4.4 x4.2 cm-sized, low-density solid mass having a thick wall from the mid to lower pole of the left kidney. A peripheral blood analysis revealed blastic transformation of CML. The biopsied renal parenchyme was diffusely infiltrated by sheets of immature myeloid cells, polymorphonuclear leukocytes, and occasional eosinophils. Most of the infiltrating cells were positive for anti-neutrophil elastase, but negative for lymphoid markers. Therefore, differential diagnosis of a kidney tumor during the course of CML, especially in the time of blastic transformation, should be performed.
Aged ; Female ; Humans ; Kidney Neoplasms/*pathology ; Leukemia, Myeloid, Chronic/*pathology

No abstract available.
Humans ; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Chronic neutrophilic leukemia (CNL) is a rare myeloproliferative neoplasm (MPN) characterized by persistent peripheral blood neutorphilia, bone marrow hypercellularity of neutrophilic granulocyte proliferation and hepatosplenomegaly. Acquired somatic mutation, JAK2 V617F, is the only molecular marker known to have association with classic BCR-ABL1 negative MPNs. However, JAK2 V617F has been detected occasionally in other MPNs such as CNL or other disease entities. We experienced a case of CNL with JAK2 V617F mutation. The patient was diagnosed according to the 2008 WHO classification criteria, and developed AML 9 months after the diagnosis of CNL. The JAK2 V617F was detected in the bone marrow throughout the clinical course. More cases are needed to establish the role of JAK2 V617F in the pathogenesis, prognosis and disease course of CNL.
Bone Marrow ; Granulocytes ; Humans ; Leukemia, Myeloid, Acute ; Leukemia, Neutrophilic, Chronic ; Neutrophils ; Prognosis

A 14 years old female patient with chronic myelocytic leukemia was presented. Characteristic blood features of peripheral blood smear and bone marrow findings, clinical symptoms and signs, Philadelphia chromosome are confirmative for the diagnosis of the disease. Pertinent literatures and references were also reviewed briefly.
Adolescent ; Bone Marrow ; Diagnosis ; Female ; Humans ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive ; Leukemia, Myeloid* ; Philadelphia Chromosome*